EANS-Adhoc: Sartorius AG / Sales revenue and earnings for the Biotechnology Division further increased | Significantly improved order situation and positive earnings for the Mechatronics Division | Double-digit operating EBITA margin reported at Group level | Expectations for 2010 confirmed

ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.


In the first three months, the Sartorius Group received orders valued at EUR167.2 million (mn), up from EUR157.0 mn and thus 6.5% (currency-adjusted:
+7.6%) more than in the year-earlier quarter. Sales revenue rose 3.0% (currency-adj.: +4.1%) to EUR150.4 mn from EUR146.0 mn a year ago. For the Biotechnology Division, order intake climbed 5.8% (currency-adj.: +6.7%) to EUR110.4 mn from EUR104.4 mn a year earlier, and sales revenue grew 3.7% (currency-adj.: +4.8%) to EUR100.1 mn from EUR96.6 mn in the prior-year quarter. The Mechatronics Division obtained orders worth EUR56.8 mn (previous year:
EUR52.6 mn) and thus significantly boosted its order volume by 7.9% (currency-adj.: +9.2%). Sales revenue for the Mechatronics Division edged up 1.8% (currency-adj.: +2.8%) from EUR49.5 mn to EUR50.4 mn.

Consolidated earnings before interest, taxes and amortization and adjusted for extraordinary expenses of EUR0.9 mn (underlying EBITA) rose year on year from EUR10.9 mn to EUR16.4 mn; the respective margin, from 7.5% to 10.9%. The Biotechnology Division contributed EUR14.6 mn, up from EUR12.8 mn a year ago, and raised its margin year on year from 13.3% to 14.6%. Compared with the previous year (-EUR1.9 mn), the Mechatronics Division swung back to profitability, contributing positive earnings of EUR1.8 mn and increasing its margin from -3.9% to +3.7%.

Excluding non-cash amortization, consolidated adjusted net profit after minority interest is at EUR6.9 mn, up from EUR2.4 mn a year ago; the respective earnings per share, at EUR0.41, up from EUR0.14. The ratio of net debt to EBITDA is at 2.6.

The results achieved meet our expectations for both divisions and confirm our outlook for the current fiscal year. This outlook forecasts sales growth of slightly above 5% in constant currencies and further improvement of the operating EBITA margin by one to two percentage points as well as a significantly positive operating cash flow.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the results with analysts and investors on Wednesday, April 21, 2010, at 4:30 p.m. Central European Time in a webcast teleconference. You may dial into the telecon-ference starting at 4:15 p.m. CET at the following numbers: Germany +49 (0)69 9897 2623; France +33 (0)1 70 99 42 85; UK +44 (0)20 7138 0843; USA +1 212 444 0895
The dial-in code is: 9427275
The webcast and presentation can be viewed at www.sartorius.com.

end of announcement euro adhoc

issuer: Sartorius AG Weender Landstr. 94-108 D-37075 Göttingen phone: +49 (0)551 308-0 FAX: +49 (0)551 308-3289 mail: info.investor@sartorius.com WWW: http://www.sartorius.com sector: Biotechnology ISIN: DE0007165607, DE0007165631 indexes: CDAX, Prime All Share, Technology All Share

stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, Hannover, München language: English

Rückfragen & Kontakt:

Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com